<![CDATA[Carotuximab/Apalutamide Further Extends PFS in Metastatic CRPC]]>

Phase 2positiveCarotuximabApalutamidePositive

AI Analysis

Summary

Interim Phase 2 data demonstrate carotuximab combined with apalutamide substantially extends progression-free survival to 17.7 months compared to 2 months with apalutamide monotherapy in metastatic castration-resistant prostate cancer.

Clinical Trial Data

Phase

Primary Endpoint

Met

Outcome Details

Median PFS of 17.7 months with carotuximab plus apalutamide versus 2 months with apalutamide alone in metastatic CRPC

Importance:6/10

Sentiment:

0.80

oncologyprostate cancerCRPCcombination therapyclinical data

Related Companies

$ALLO

Read the original article

Published by Cancer Network on October 8, 2026 5:00 PM

Read Original